v3.25.2
Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
Total
At The Market Offering
Pre-Funded Warrants
Common Stock
Common Stock
At The Market Offering
Common Stock
Pre-Funded Warrants
Additional Paid-in Capital
Additional Paid-in Capital
At The Market Offering
Additional Paid-in Capital
Pre-Funded Warrants
Accumulated Other Comprehensive Income (Loss)
Accumulated Deficit
Beginning balance at Dec. 31, 2023 $ 287,506     $ 20     $ 1,625,637     $ (60) $ (1,338,091)
Beginning balance (in shares) at Dec. 31, 2023       197,857              
Issuance of common stock, net of offering costs (in shares)         150 21,773          
Issuance of common stock, net of offering costs   $ 1,037 $ 180,008     $ 2   $ 1,037 $ 180,006    
Fees incurred related to common stock financings   (113) $ (9,741)                
Vesting of restricted stock (in shares)       386              
Exercise of stock options 4,929           4,929        
Exercise of stock options (in shares)       1,120              
Stock-based compensation expense 9,092           9,092        
Unrealized gain (loss) on marketable securities, net 45                 45  
Net loss (107,475)                   (107,475)
Ending balance at Mar. 31, 2024 375,142     $ 22     1,820,701     (15) (1,445,566)
Ending balance (in shares) at Mar. 31, 2024       221,286              
Beginning balance at Dec. 31, 2023 287,506     $ 20     1,625,637     (60) (1,338,091)
Beginning balance (in shares) at Dec. 31, 2023       197,857              
Net loss (157,766)                    
Ending balance at Jun. 30, 2024 339,649     $ 22     1,835,503     (19) (1,495,857)
Ending balance (in shares) at Jun. 30, 2024       222,209              
Beginning balance at Mar. 31, 2024 375,142     $ 22     1,820,701     (15) (1,445,566)
Beginning balance (in shares) at Mar. 31, 2024       221,286              
Fees incurred related to common stock financings (16)           (16)        
Vesting of restricted stock (in shares)       52              
Exercise of stock options 2,361           2,361        
Exercise of stock options (in shares)       548              
Issuance of common stock related to employee stock purchase plan 1,077           1,077        
Issuance of common stock related to employee stock purchase plan (in shares)       323              
Stock-based compensation expense 11,380           11,380        
Unrealized gain (loss) on marketable securities, net (4)                 (4)  
Net loss (50,291)                   (50,291)
Ending balance at Jun. 30, 2024 339,649     $ 22     1,835,503     (19) (1,495,857)
Ending balance (in shares) at Jun. 30, 2024       222,209              
Beginning balance at Dec. 31, 2024 $ 250,504     $ 22     1,855,318     14 (1,604,850)
Beginning balance (in shares) at Dec. 31, 2024 223,923     223,923              
Fees incurred related to common stock financings $ (171)           (171)        
Vesting of restricted stock (in shares)       960              
Exercise of stock options 1,127     $ 1     1,126        
Exercise of stock options (in shares)       580              
Stock-based compensation expense 7,022           7,022        
Unrealized gain (loss) on marketable securities, net (14)                 (14)  
Net loss (49,389)                   (49,389)
Ending balance at Mar. 31, 2025 209,079     $ 23     1,863,295       (1,654,239)
Ending balance (in shares) at Mar. 31, 2025       225,463              
Beginning balance at Dec. 31, 2024 $ 250,504     $ 22     1,855,318     $ 14 (1,604,850)
Beginning balance (in shares) at Dec. 31, 2024 223,923     223,923              
Exercise of stock options (in shares) 600                    
Net loss $ (143,189)                    
Ending balance at Jun. 30, 2025 $ 122,556     $ 23     1,870,572       (1,748,039)
Ending balance (in shares) at Jun. 30, 2025 230,510     230,510              
Beginning balance at Mar. 31, 2025 $ 209,079     $ 23     1,863,295       (1,654,239)
Beginning balance (in shares) at Mar. 31, 2025       225,463              
Issuance of common stock, net of offering costs (in shares)         170            
Issuance of common stock, net of offering costs   315           $ 315      
Exercise of pre-funded warrants (in shares)       4,445              
Fees incurred related to common stock financings   $ (174)                  
Vesting of restricted stock (in shares)       203              
Exercise of stock options 148           148        
Exercise of stock options (in shares)       102              
Issuance of common stock related to employee stock purchase plan 185           185        
Issuance of common stock related to employee stock purchase plan (in shares)       127              
Stock-based compensation expense 6,629           6,629        
Net loss (93,800)                   (93,800)
Ending balance at Jun. 30, 2025 $ 122,556     $ 23     $ 1,870,572       $ (1,748,039)
Ending balance (in shares) at Jun. 30, 2025 230,510     230,510